A drug-inducible CRISPR/Cas9 system for gene transcriptional activation
A gene transcription and inducible technology, applied in the field of molecular biology, can solve problems such as the inapplicability of regulatory drugs or methods
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0062] Example 1 Direct fusion drug-inducible CRISPR / Cas9 system
[0063] Build method:
[0064] The drug-inducible gene editing system constructed by the present invention includes the following two parts:
[0065] (1) Design sgRNAs targeting specific gene transcriptional activation sites.
[0066] (2) Put one / two ERs T2 inserted between dCas9 and VPH or VPR (dCas9-E-VPH or dCas9-2E-VPH or dCas9-E-VPR or dCas9-2E-VPR) or fused to the C-terminus of dCas9-VPH / VPR (dCas9 -VPH-E or dCas9-VPH-2E or dCas9-VPR-E or dCas9-VPR-2E)
[0067] The sgRNA and expression fusion protein dCas9-E-VPH or dCas9-2E-VPH or dCas9-VPH-E or dCas9-VPH-2E or dCas9-E-VPR or dCas9-2E-VPR or dCas9-VPR-E or dCas9 -VPR-2E vectors are present in different plasmids or in the same plasmid.
[0068] The source of each part of the plasmid is as follows:
[0069] The dCas9 element was amplified from the plasmid pMSCV-LTR-dCas9-VP64-BFP (from Feng Zhang's laboratory, Addgene plasmid#42230). The ERT2 element ...
Embodiment 2
[0073] Example 2 HIT-SAM system
[0074] Build method:
[0075] The drug-inducible gene editing system constructed by the present invention includes the following two parts:
[0076] (1) Design sgRNAs targeting specific gene transcriptional activation sites.
[0077] (2) Fusing NLS to the C-terminus of dCas9 to obtain dCas9-NLS;
[0078] (3) Put one / two ERs T2 Insertion between MCP and ADs yields MCP-E-ADs or MCP-2E-ADs.
[0079] ADs include V, P, R, H and any combination thereof.
[0080] The sgRNA, the vector expressing the fusion protein dCas9-NLS and the vector expressing the fusion protein MCP-2E-VPH respectively exist in different plasmids or the same plasmid.
[0081] The source of each part of the plasmid is as follows:
[0082] Cas9, ER T2 Same as Example 1 with each transcription factor.
[0083] NLS was amplified from plasmid pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgeneplasmid#42230).
[0084] Construction of MCP Plasmid First, MCP was obtained by PCR amplific...
Embodiment 3
[0087] Example 3 HIT-SunTag System
[0088] Build method:
[0089] The drug-inducible gene editing system constructed by the present invention includes the following two parts:
[0090] (1) Design sgRNAs targeting specific gene transcriptional activation sites.
[0091] (2) Fusing NLS to the C-terminus of dCas9 to obtain dCas9-NLS, and fusing a 10×(GCN4)P peptide segment to its C-terminus to obtain dCas9-NLS-(GCN4)P;
[0092] put the two ERs T2 Inserted between scFv and VP64 to obtain scFv-2E-VP64;
[0093] put the two ERs T2 Insertion between scFv and PH yields scFv-2E-PH.
[0094] The sgRNA, the vector expressing the fusion protein dCas9-NLS-(GCN4)P, the vector expressing the fusion protein scFv-2E-VP64 and the vector expressing the fusion protein scFv-2E-PH respectively exist in different plasmids or the same plasmid.
[0095] The source of each part of the plasmid is as follows:
[0096] Cas9, NLS, ER T2 Same as Example 1 with V, P and H. Sequence references for s...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com